APA (7th ed.) Citation

Fu, Z., Cheng, X., Zhang, G., Shi, R., Zhang, L., Sun, H., & Huang, J. (2024). Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China. International Journal of Rheumatic Diseases, 27(5), 1. https://doi.org/10.1111/1756-185X.15190

Chicago Style (17th ed.) Citation

Fu, Zhong‐Chao, Xiao‐Gui Cheng, Guo‐Wen Zhang, Ran‐Geng Shi, Li‐Jun Zhang, Hai‐Tian Sun, and Jin‐Xian Huang. "Comparable Drug Levels and Immunogenicity in Patients with Axial Spondyloarthritis Treated with Adalimumab Originator and Biosimilar: A Retrospective Study from Two Centers of China." International Journal of Rheumatic Diseases 27, no. 5 (2024): 1. https://doi.org/10.1111/1756-185X.15190.

MLA (9th ed.) Citation

Fu, Zhong‐Chao, et al. "Comparable Drug Levels and Immunogenicity in Patients with Axial Spondyloarthritis Treated with Adalimumab Originator and Biosimilar: A Retrospective Study from Two Centers of China." International Journal of Rheumatic Diseases, vol. 27, no. 5, 2024, p. 1, https://doi.org/10.1111/1756-185X.15190.